tiprankstipranks
Trending News
More News >

Telix Pharmaceuticals’ Gozellix Secures Permanent HCPCS Code

Story Highlights
Telix Pharmaceuticals’ Gozellix Secures Permanent HCPCS Code

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).

Telix Pharmaceuticals announced that its next-generation PSMA PET imaging agent, Gozellix, has been granted a permanent HCPCS code by the U.S. Centers for Medicare & Medicaid Services, effective from October 1, 2025. This milestone supports provider billing and reimbursement, facilitating clinical adoption and expanded access to PSMA PET imaging for prostate cancer patients in the U.S., and marks an important step in Telix’s mission to improve access to precision medicine imaging.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company aims to address significant unmet medical needs in oncology and rare diseases with its clinical and commercial stage products.

Average Trading Volume: 1,384,665

Technical Sentiment Signal: Buy

Current Market Cap: A$8.14B

For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1